Irinotecan for children with relapsed solid tumors

Toshiji Shitara; Akira Shimada; Ryoji Hanada; Tadashi Matsunaga; Keisei Kawa; Hideo Mugishima; Tohru Sugimoto; Jun Ichi Mimaya; Atsushi Manabe; Masahito Tsurusawa; Yoshiaki Tsuchida

doi:10.1080/08880010500457152

Irinotecan for children with relapsed solid tumors

Toshiji Shitara, Akira Shimada, Ryoji Hanada, Tadashi Matsunaga, Keisei Kawa, Hideo Mugishima, Tohru Sugimoto, Jun Ichi Mimaya, Atsushi Manabe, Masahito Tsurusawa, Yoshiaki Tsuchida

研究成果 › 査読

20 被引用数 (Scopus)

抄録

Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m ²/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

本文言語	English
ページ（範囲）	103-110
ページ数	8
ジャーナル	Pediatric Hematology and Oncology
巻	23
号	2
DOI	https://doi.org/10.1080/08880010500457152
出版ステータス	Published - 3月 2006
外部発表	はい

ASJC Scopus subject areas

小児科学、周産期医学および子どもの健康
血液学
腫瘍学

文献へのアクセス

10.1080/08880010500457152

他のファイルとリンク

引用スタイル

@article{44dfd769c62045a186a9bd3e4951ba38,

title = "Irinotecan for children with relapsed solid tumors",

abstract = "Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m 2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.",

keywords = "Clinical trials, Irinotecan, Nephroblastoma, Neuroblastoma, Rhabdomyosarcoma",

author = "Toshiji Shitara and Akira Shimada and Ryoji Hanada and Tadashi Matsunaga and Keisei Kawa and Hideo Mugishima and Tohru Sugimoto and Mimaya, {Jun Ichi} and Atsushi Manabe and Masahito Tsurusawa and Yoshiaki Tsuchida",

note = "Funding Information: The authors are deeply grateful to Cynthia Yenches for editorial assistance and to K. Asami, B. Higuchi, A. Kawaguchi, and T. Hori for their contributions to the study. This work was supported by a Grant-in-Aid for Cancer Research (No. 9-14) from the Ministry of Health, Labour and Welfare of the Government of Japan.",

year = "2006",

month = mar,

doi = "10.1080/08880010500457152",

language = "English",

volume = "23",

pages = "103--110",

journal = "Pediatric Hematology and Oncology",

issn = "0888-0018",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Irinotecan for children with relapsed solid tumors

AU - Shitara, Toshiji

AU - Shimada, Akira

AU - Hanada, Ryoji

AU - Matsunaga, Tadashi

AU - Kawa, Keisei

AU - Mugishima, Hideo

AU - Sugimoto, Tohru

AU - Mimaya, Jun Ichi

AU - Manabe, Atsushi

AU - Tsurusawa, Masahito

AU - Tsuchida, Yoshiaki

N1 - Funding Information: The authors are deeply grateful to Cynthia Yenches for editorial assistance and to K. Asami, B. Higuchi, A. Kawaguchi, and T. Hori for their contributions to the study. This work was supported by a Grant-in-Aid for Cancer Research (No. 9-14) from the Ministry of Health, Labour and Welfare of the Government of Japan.

PY - 2006/3

Y1 - 2006/3

N2 - Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m 2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

AB - Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m 2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

KW - Clinical trials

KW - Irinotecan

KW - Nephroblastoma

KW - Neuroblastoma

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=31644434536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31644434536&partnerID=8YFLogxK

U2 - 10.1080/08880010500457152

DO - 10.1080/08880010500457152

M3 - Article

C2 - 16651238

AN - SCOPUS:31644434536

SN - 0888-0018

VL - 23

SP - 103

EP - 110

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

IS - 2

ER -

Irinotecan for children with relapsed solid tumors

抄録

ASJC Scopus subject areas

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル